The clinical efficacy of mometasone furoate in multi-lamellar emulsion for eczema: A double-blinded crossover study

Duk Han Kim, Hyun Jong Lee, Chun Wook Park, Kyu Han Kim, Kwanghoon Lee, Byung In Ro, Sang Hyun Cho

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Topical application of corticosteroids also has an influence on skin barrier impairment. Physiological lipid mixtures, such as multi- lamellar emulsion (MLE) containing a natural lipid component leads to effective recovery of the barrier function. Objective: The purpose of this study was to conduct an evaluation of the therapeutic efficacy and skin barrier protection of topical mometasone furoate in MLE. Methods: A multi-center randomized, double-blind, controlled study was performed to assess the efficacy and safety of mometasone furoate cream in MLE for Korean patients with eczema. The study group included 175 patients with eczema, who applied either mometasone furoate in MLE cream or methylprednisolone aceponate cream for 2 weeks. Treatment efficacy was evaluated using the physician's global assessment of clinical response (PGA), trans-epidermal water loss (TEWL), and visual analogue scale (VAS) for pruritus. Patients were evaluated using these indices at days 4, 8, and 15. Results: Comparison of PGA score, TEWL, and VAS score at baseline with those at days 4, 8, and 15 of treatment showed a significant improvement in both groups. Patients who applied mometasone furoate in MLE (74.8%) showed better results (p 0.05) than those who applied methylprednisolone aceponate (47.8%). The TEWL improvement ratio was higher in the mometasone furoate in MLE group than that in the methylprednisolone aceponate group, and VAS improvement was also better in the mometasone furoate in MLE group. Conclusion: Mometasone furoate in MLE has a better therapeutic efficacy as well as less skin barrier impairment than methylprednisolone aceponate.

Original languageEnglish
Pages (from-to)17-22
Number of pages6
JournalAnnals of Dermatology
Volume25
Issue number1
DOIs
Publication statusPublished - 2013 Feb 1

Fingerprint

Mometasone Furoate
methylprednisolone aceponate
Eczema
Emulsions
Cross-Over Studies
Visual Analog Scale
Prostaglandins A
Skin
Water
Lipids
Recovery of Function
Pruritus
Double-Blind Method

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

Kim, Duk Han ; Lee, Hyun Jong ; Park, Chun Wook ; Kim, Kyu Han ; Lee, Kwanghoon ; Ro, Byung In ; Cho, Sang Hyun. / The clinical efficacy of mometasone furoate in multi-lamellar emulsion for eczema : A double-blinded crossover study. In: Annals of Dermatology. 2013 ; Vol. 25, No. 1. pp. 17-22.
@article{f45492f75af442d8916b8fbd3c4cedd9,
title = "The clinical efficacy of mometasone furoate in multi-lamellar emulsion for eczema: A double-blinded crossover study",
abstract = "Topical application of corticosteroids also has an influence on skin barrier impairment. Physiological lipid mixtures, such as multi- lamellar emulsion (MLE) containing a natural lipid component leads to effective recovery of the barrier function. Objective: The purpose of this study was to conduct an evaluation of the therapeutic efficacy and skin barrier protection of topical mometasone furoate in MLE. Methods: A multi-center randomized, double-blind, controlled study was performed to assess the efficacy and safety of mometasone furoate cream in MLE for Korean patients with eczema. The study group included 175 patients with eczema, who applied either mometasone furoate in MLE cream or methylprednisolone aceponate cream for 2 weeks. Treatment efficacy was evaluated using the physician's global assessment of clinical response (PGA), trans-epidermal water loss (TEWL), and visual analogue scale (VAS) for pruritus. Patients were evaluated using these indices at days 4, 8, and 15. Results: Comparison of PGA score, TEWL, and VAS score at baseline with those at days 4, 8, and 15 of treatment showed a significant improvement in both groups. Patients who applied mometasone furoate in MLE (74.8{\%}) showed better results (p 0.05) than those who applied methylprednisolone aceponate (47.8{\%}). The TEWL improvement ratio was higher in the mometasone furoate in MLE group than that in the methylprednisolone aceponate group, and VAS improvement was also better in the mometasone furoate in MLE group. Conclusion: Mometasone furoate in MLE has a better therapeutic efficacy as well as less skin barrier impairment than methylprednisolone aceponate.",
author = "Kim, {Duk Han} and Lee, {Hyun Jong} and Park, {Chun Wook} and Kim, {Kyu Han} and Kwanghoon Lee and Ro, {Byung In} and Cho, {Sang Hyun}",
year = "2013",
month = "2",
day = "1",
doi = "10.5021/ad.2013.25.1.17",
language = "English",
volume = "25",
pages = "17--22",
journal = "Annals of Dermatology",
issn = "1013-9087",
publisher = "Korean Dermatological Association",
number = "1",

}

The clinical efficacy of mometasone furoate in multi-lamellar emulsion for eczema : A double-blinded crossover study. / Kim, Duk Han; Lee, Hyun Jong; Park, Chun Wook; Kim, Kyu Han; Lee, Kwanghoon; Ro, Byung In; Cho, Sang Hyun.

In: Annals of Dermatology, Vol. 25, No. 1, 01.02.2013, p. 17-22.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The clinical efficacy of mometasone furoate in multi-lamellar emulsion for eczema

T2 - A double-blinded crossover study

AU - Kim, Duk Han

AU - Lee, Hyun Jong

AU - Park, Chun Wook

AU - Kim, Kyu Han

AU - Lee, Kwanghoon

AU - Ro, Byung In

AU - Cho, Sang Hyun

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Topical application of corticosteroids also has an influence on skin barrier impairment. Physiological lipid mixtures, such as multi- lamellar emulsion (MLE) containing a natural lipid component leads to effective recovery of the barrier function. Objective: The purpose of this study was to conduct an evaluation of the therapeutic efficacy and skin barrier protection of topical mometasone furoate in MLE. Methods: A multi-center randomized, double-blind, controlled study was performed to assess the efficacy and safety of mometasone furoate cream in MLE for Korean patients with eczema. The study group included 175 patients with eczema, who applied either mometasone furoate in MLE cream or methylprednisolone aceponate cream for 2 weeks. Treatment efficacy was evaluated using the physician's global assessment of clinical response (PGA), trans-epidermal water loss (TEWL), and visual analogue scale (VAS) for pruritus. Patients were evaluated using these indices at days 4, 8, and 15. Results: Comparison of PGA score, TEWL, and VAS score at baseline with those at days 4, 8, and 15 of treatment showed a significant improvement in both groups. Patients who applied mometasone furoate in MLE (74.8%) showed better results (p 0.05) than those who applied methylprednisolone aceponate (47.8%). The TEWL improvement ratio was higher in the mometasone furoate in MLE group than that in the methylprednisolone aceponate group, and VAS improvement was also better in the mometasone furoate in MLE group. Conclusion: Mometasone furoate in MLE has a better therapeutic efficacy as well as less skin barrier impairment than methylprednisolone aceponate.

AB - Topical application of corticosteroids also has an influence on skin barrier impairment. Physiological lipid mixtures, such as multi- lamellar emulsion (MLE) containing a natural lipid component leads to effective recovery of the barrier function. Objective: The purpose of this study was to conduct an evaluation of the therapeutic efficacy and skin barrier protection of topical mometasone furoate in MLE. Methods: A multi-center randomized, double-blind, controlled study was performed to assess the efficacy and safety of mometasone furoate cream in MLE for Korean patients with eczema. The study group included 175 patients with eczema, who applied either mometasone furoate in MLE cream or methylprednisolone aceponate cream for 2 weeks. Treatment efficacy was evaluated using the physician's global assessment of clinical response (PGA), trans-epidermal water loss (TEWL), and visual analogue scale (VAS) for pruritus. Patients were evaluated using these indices at days 4, 8, and 15. Results: Comparison of PGA score, TEWL, and VAS score at baseline with those at days 4, 8, and 15 of treatment showed a significant improvement in both groups. Patients who applied mometasone furoate in MLE (74.8%) showed better results (p 0.05) than those who applied methylprednisolone aceponate (47.8%). The TEWL improvement ratio was higher in the mometasone furoate in MLE group than that in the methylprednisolone aceponate group, and VAS improvement was also better in the mometasone furoate in MLE group. Conclusion: Mometasone furoate in MLE has a better therapeutic efficacy as well as less skin barrier impairment than methylprednisolone aceponate.

UR - http://www.scopus.com/inward/record.url?scp=84877290769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877290769&partnerID=8YFLogxK

U2 - 10.5021/ad.2013.25.1.17

DO - 10.5021/ad.2013.25.1.17

M3 - Article

C2 - 23467551

AN - SCOPUS:84877290769

VL - 25

SP - 17

EP - 22

JO - Annals of Dermatology

JF - Annals of Dermatology

SN - 1013-9087

IS - 1

ER -